PRAX News and Press, Praxis Precision Medicines Inc. From 02/13/26

2026-02-13 07:54:09 ET On Feb. 12, Soleus Capital Management, L.P. disclosed a buy of 629,398 shares of Celcuity (NASDAQ:CELC) in a Securities and Exchange Commission (SEC) filing Celcuity is a clinical-stage biotechnology firm focused on innovative cancer diagnostics and ta...

2026-02-10 16:15:00 ET Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to b iotech ETFs, they give sector participants exposure to many biotech companies via one vehicle. ETFs are a popular choice as they allow ...

BOSTON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report its financial results for the fourth quarter and full year ended Dec...

2026-01-26 09:19:21 ET Fast Facts About the Direxion Daily S&P Biotech Bear 3x Shares ETF Read the full article on Seeking Alpha For further details see: LABD: ETF To Benefit From Downturns In The Biotech Industry

A look at the top 10 most actives in the United States Walmart Inc. (WMT) rose 0.4% to $119.7 on volume of 415,144,621 shares Venus Concept Inc. (VERO) rose 459.4% to $8 on volume of 308,915,099 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 3.7% to $2.09 on volume of 306,40...

BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced the appointment of world-renowned neurologist and epilepsy authority Dr. Orrin Devi...

Two NDA submissions expected by mid-February 2026 for ulixacaltamide in essential tremor and relutrigine in SCN2A/8A-DEEs, both with Breakthrough Therapy Designation from the FDA Multiple registrational readouts expected across vormatrigine, relutrigine and elsunersen in 2026 Strong balan...

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation–inhibition im...

2026-01-06 23:48:17 ET Read the full article on Seeking Alpha For further details see: Praxis Precision prices $575M stock offering at $260

BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalan...